Longitudinal treatment patterns in myasthenia gravis: An analysis from the prospective Dutch-Belgian patient registry
Journal of Neuromuscular Diseases · 2025
DOI: 10.1177/22143602251405924 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, 2025. Verfasst von Linda Remijn-Nelissen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Myasthenia Gravis, Adrenal Cortex Hormones, Immunosuppressive Agents. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB Pharma.
Abstract (Originalsprache)
Background
Understanding treatment patterns in myasthenia gravis (MG) is crucial for clinical practice. However, longitudinal data are limited.
Objective
This study aimed to provide an overview of treatment patterns in different subgroups throughout the disease course.
Methods
All adult patients with acetylcholine receptor (AChR), muscle-specific kinase (MuSK), or seronegative MG enrolled in the Dutch-Belgian myasthenia registry were included. AChR-MG patients were classified into early-onset (EOMG) (≤50 years) and late-onset (LOMG) (>50 years) MG. Mixed-effects regression was used to compare differences between the different subgroups.
Results
A total of 506 patients were included (147 AChR EOMG, 265 AChR LOMG, 26 MuSK, and 94 seronegative MG patients). Data were available within a year of diagnosis for 84 patients. Most patients initially started treatment with pyridostigmine (93%; 78/84), followed by corticosteroids (52%; 44/84) and azathioprine or mycophenolate mofetil (30%; 25/84). After ten years, the use of pyridostigmine (65%; 54/83) and corticosteroid use (36%; 30/83) declined, whereas the use of azathioprine and mycophenolate mofetil increased (55%; 46/83). Seronegative patients received fewer treatments than AChR MG patients, independent of functional status and disease duration (OR 0.38, 95% CI 0.17–0.84, p = 0.018), and were less likely to use corticosteroids (OR 0.15, 95% CI [0.05–0.41], p < 0.001). Patients with LOMG reported more frequently immunosuppressive use compared to patients with EOMG (OR 4.69, 95% CI 1.16–19.02, p = 0.031).
Conclusions
This analysis offers valuable insights into treatment patterns in different subgroups of patients with MG. A substantial proportion of patients continues to rely on corticosteroids, suggesting an ongoing need for alternative treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
ORCID-Profile: Linda Remijn-Nelissen, Martijn R Tannemaat, Jan Jgm Verschuuren
Förderung
- UCB Pharma
Zitieren
APA
Remijn-Nelissen, L., Tannemaat, M. R., & Verschuuren, J. J. (2025). Longitudinal treatment patterns in myasthenia gravis: An analysis from the prospective Dutch-Belgian patient registry. Journal of Neuromuscular Diseases. https://doi.org/10.1177/22143602251405924
Vancouver
Remijn-Nelissen L, Tannemaat MR, Verschuuren JJ. Longitudinal treatment patterns in myasthenia gravis: An analysis from the prospective Dutch-Belgian patient registry. Journal of Neuromuscular Diseases. 2025. doi:10.1177/22143602251405924
BibTeX
@article{RemijnNelissen2025,
author = {Remijn-Nelissen, Linda and Tannemaat, Martijn R and Verschuuren, Jan Jgm},
title = {Longitudinal treatment patterns in myasthenia gravis: An analysis from the prospective Dutch-Belgian patient registry},
journal = {Journal of Neuromuscular Diseases},
year = {2025},
doi = {10.1177/22143602251405924}
}
EUVIMED